Researchers in Sweden have unveiled a groundbreaking microscale device designed for implantation in the eye, unlocking new possibilities for cell-based treatments targeting diabetes and other diseases. Crafted through 3D printing by a collaborative effort between KTH Royal Institute of Technology and Karolinska Institutet, the device aims to encapsulate insulin-producing pancreatic cells along with electronic sensors. The team’s findings, outlined in the journal Advanced Materials, showcase the potential for innovative cell-based therapies, particularly for diabetes, utilizing the eye as a strategic platform.

Precision Implantation Without Sutures

The collaboration between KTH and Karolinska Institutet allows for the precise positioning of micro-organs, specifically pancreatic islets or islets of Langerhans, within the eye without the need for sutures. This opens avenues for treating Type 1 or Type 2 diabetes by leveraging the unique immune-privileged and transparent characteristics of the eye. Anna Herland, senior lecturer in the Division of Bionanotechnology at SciLifeLab at KTH and the AIMES research center at KTH and Karolinska Institutet, emphasizes the eye’s suitability for this technology due to its immunity and transparent attributes, facilitating real-time observations of the implant’s behavior.

Samay, a US-based startup, has revealed positive outcomes for its AI-assisted wearable technology, Sylvee, showcasing a remarkable 90% accuracy in diagnosing chronic obstructive pulmonary disease (COPD). The passive remote monitoring platform, in collaboration with the Pulmonary, Critical Care, and Sleep Disorders Institute of South Florida, delivered results nearly equivalent to the current standard pulmonary function test (PFT).

COPD, a prevalent chronic respiratory ailment affecting millions globally, is the third leading cause of death worldwide, impacting around 12.5 million people in the United States alone.

In recent years, the groundbreaking success of CAR T-cell therapies in treating hard-to-treat blood cancers has been a beacon of hope. However, translating this success to solid tumors, which constitute the majority of cancer cases, has proven challenging. Encouragingly, recent trial results, such as those from BioNTech’s BNT211, suggest that researchers are making strides in developing next-generation CAR T therapies for solid tumors.

Overcoming Solid Tumor Challenges: Traditionally, CAR T therapies have excelled in blood cancers, leveraging engineered T cells to utilize the patient’s immune system. Solid tumors present unique challenges, including finding the right protein to target without harming healthy tissues. BioNTech’s approach, targeting Claudin-6, a protein present in fetal tissue and certain cancers but absent in healthy adult tissue, has shown promise in mitigating this challenge.

In a significant leap forward, the Food and Drug Administration (FDA) is moving closer to approving the first therapy utilizing CRISPR gene-editing technology. The potential approval of Exa-cel, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, marks a milestone in the treatment of hereditary disorders such as sickle cell disease.

Why it Matters: Directly editing genes within a patient’s body could be a life-altering breakthrough for individuals grappling with debilitating hereditary conditions, particularly sickle cell disease. This innovative therapy focuses on addressing the root causes of the disease.

The Exa-cel Therapy: Exa-cel, designed for patients aged 12 and above, offers a one-time treatment approach. The therapy involves editing a patient’s stem cells to produce elevated levels of fetal hemoglobin. This specific approach aims to counteract the impact of defective hemoglobin prevalent in individuals with sickle cell disease.